EGFR and lung adenocarcinoma: Subgroup analysis from LUX-LUNG 3 and LUX-LUNG 6 studies demonstrated a significant overall survival benefit for afatinib compared to chemotherapy in UICC stage IIIB/IV lung adenocarcinoma patients with 19del-EGFR mutation (10).